Kidney Week

Abstract: FR-PO461

Impact of Hemodiafiltration on Serum Interferon Levels in Patients with CKD: Results from the HDFIT Study

Session Information

• Hemodialysis and Frequent Dialysis - IV
  November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

• 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

• Almeida, Ana clara Simões flórido, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil

Ana clara Simões flórido Almeida,

• Franco de Lima, Luiz Felipe, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil

Luiz Felipe Franco de Lima,

• Guedes, Murilo Henrique, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil

Murilo Henrique Guedes,

• Silva, Caroline, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil

Caroline Silva,

• Barra, Ana Beatriz Lesqueves, Fresenius Medical Care, Rio de Janeiro, Brazil

Ana Beatriz Lesqueves Barra,

• Canziani, Maria Eugenia F., Federal University of Sao Paulo, Sao Paulo, Brazil

Maria Eugenia F. Canziani,

• Cuvello neto, Americo Lourenço, Hospital Alemão Oswaldo Cruz, Sao Paulo, Brazil

Americo Lourenço Cuvello neto,

• Poli de Figueiredo, Carlos Eduardo, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

Carlos Eduardo Poli de Figueiredo,

• Gadonski, Giovani, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

Giovani Gadonski,

• Pecoits-Filho, Roberto, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Roberto Pecoits-Filho,

• Moreno-Amaral, Andrea Novais, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil

Andrea Novais Moreno-Amaral,

Background

Interferons are cytokines that play an important role in immunomodulatory processes. Hemodiafiltration (HDF) optimizes the removal of medium-sized molecules, and although HDF has been associated with a reduction in pro-inflammatory biomarkers, its effect on serum interferon levels have not been described until the present.

Methods

HDFIT was a multicenter randomized controlled trial comparing HDF to high flux hemodialysis, in which biosamples were collected at baseline and after 6 months (HD n=67; HDF n=63). Cytokines measurement was performed through Milliplex^â Human Cytokine Magnetic Bead Panel (IFN-g and IFN-a2) (EMD Milipore Corporation, USA).

Results

There was no significant difference in patients demographic characteristics between groups regarding age (53 years old in HD ± 15 vs 53 ± 16 in HDF), gender (68% male in HD vs 71% in HDF) and diabetes (44% in HD vs 28% in HDF). The mean difference (95% confidence interval) between HDF and HD in 6 months was 0.18 (-0.16 — 0.53) and 0.49 (-0.03 — 1.01) for IFN-g and IFN-a2, respectively (Figure 1). This effect was mainly driven by a reduction in interferons observed in the HD group (IFN-a2 0.35 ± 1.8 vs 0.07 ± 1.8 and IFN-g 1.21 ± 1.08 vs 1.11 ± 1.08) and their maintenance on HDF group (IFN-a2 0.78 ± 1.79 vs 0.78 ± 1.79 and IFN-g 1.55 ± 1.12 vs 1.46 ± 1.12).

Conclusion

This study demonstrates that after 6 months of treatment, patients on HDF maintained the concentrations of circulating interferons (IFN-a2 and IFN-g) compared to HD, where the concentration of IFN decreased over time. Based on the knowledge of IFN actions and functions, these findings suggest that HDF may have immunomodulatory effects that could be beneficial to patients with CKD.